Showing 288 results for "chronic thromboembolic pulmonary hypertension"

Filter By

People with chronic thromboembolic pulmonary hypertension (CTEPH) are more likely to have a depressive temperament, finds a Japanese study, “Depressive Status in Patients With Chronic Thromboembolic Pulmonary Hypertension” that appeared in the Circulation Journal. CTEPH is a progressive disease characterized by increasing pulmonary vascular resistance. Although the underlying…

The new pulmonary endarterectomy (PEA) surgery simulator — a 3D device developed by the National Research Council of Canada with support from Bayer — could potentially improve the lives of thousands of Canadians with chronic thromboembolic pulmonary hypertension (CTEPH). The first-of-its-kind simulator will allow surgeons to train more efficiently for surgery to treat CTEPH, a…

Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare form of pulmonary hypertension (PH), a disease associated with abnormally high pressure in the blood vessels of the lungs, caused by the formation of blood clots. CTEPH also can be referred to as group 4 PH, the World Health Organization classification that…

An expert panel convened by the American Lung Association and the Pulmonary Hypertension Association has developed practical flowcharts to help U.S. healthcare providers diagnose and treat pulmonary hypertension (PH). The meeting aimed to guide providers through the most recent European guidelines for PH diagnosis and treatment. The…

Pulmonary hypertension life expectancy varies broadly, depending on factors such as disease type and treatment access. Still, the outlook has greatly improved with modern treatments, allowing many people with the rare disease to live full and active lives. Abnormally high pressure in the blood vessels that carry blood from…

Adempas (riociguat) is an oral therapy approved to improve exercise capacity and World Health Organization functional class in adults with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension, and to delay clinical worsening in PAH. It's available as oral tablets to be taken three times daily.

Balloon pulmonary angioplasty (BPA) led to significant clinical improvements for people with chronic thromboembolic pulmonary hypertension (CTEPH) when used as an initial therapy or after a pulmonary endarterectomy (PEA) surgery, according to a global observational study. “Our data are in line with previous reports on changes of clinical and…

Pulmonary arterial dilatation — the abnormal widening of the main pulmonary artery leading from the heart — was a common feature among people with pulmonary hypertension (PH) in a large-scale study. The clinical characteristics related to a dilated pulmonary artery, such as heart function and blood flow parameters, varied widely…